NICE confirmed that they will be prioritising work that is therapeutically critical or relates to ad...
Read more"Payer" generally refers to people or bodies other than the patient that finance or refund the cost ...
Read moreDifferences in market access and reimbursement processes are an important factor in determining the ...
Read moreThe final details of the decree may differ from those detailed above, making the precise nature of t...
Read more"Market Access" describes activities and processes that pharmaceutical and biotech companies underta...
Read morePrescription drug prices in the US rank among the highest in the world and the US spent $1220 on ph...
Read moreThe Westminster Health Forum organise senior level conferences on public policy relating to health a...
Read moreWith the UKs withdrawal from the European Union, NICE’s relationship with EMA and indeed, the para...
Read moreNHS England is developing a new Commercial Framework, outlining potential opportunities for commerci...
Read moreMaximising the cost-saving potential of biosimilars remains a topic of much interest to payers and p...
Read more